Melanoma & Skin Cancer | Specialty

The melanoma & skin cancer condition center is a comprehensive resource for clinical news and expert insights on melanoma & skin cancer. Read more at OncLive.

Dr Akkooi on Pathologic Review Discrepancies and Overtreatment Risks in Metastatic Melanoma

January 27th 2025

Alexander C.J. Van Akkooi, MD, PhD, FRACS, discusses how discrepancies in local and central pathologic review can expose patients to potential toxicities associated with overtreatment for metastatic melanoma.

The OncFive: Top Oncology Articles for the Week of 1/19

January 25th 2025

Treosulfan wins FDA approval for allHCT conditioning in AML and MDS, RP1/nivolumab gets priority review in melanoma, and more this week from OncLive.

FDA Grants Priority Review to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy

January 21st 2025

The FDA granted priority review to the BLA for RP1 plus nivolumab in advanced melanoma following progression on an anti–PD-1 agent.

Continuous Synthetic Hypericin Generates Responses in Early-Stage Cutaneous T-Cell Lymphoma

January 14th 2025

Treatment with synthetic hypericin for up to 12 months produced responses in early-stage cutaneous T-cell lymphoma.

Dr Chmielowski on the Rationale for Investigating Oncolytic Viruses in Melanoma

January 10th 2025

Bartosz Chmielowski, MD, PhD, discusses the rationale for investigating oncolytic viruses in melanoma.

Phase 3 Study of Ameluz-PDT in Superficial Basal Cell Carcinoma Reaches 1-Year Follow-Up to Support FDA sNDA Submission

January 8th 2025

The phase 3 ALA-BCC-CT013 study of Ameluz and RhodoLED PDT in sBCC had its last enrolled patient complete a 1-year follow-up visit.

The OncFive: Top Oncology Articles for the Week of 12/29

January 4th 2025

This week’s top 5 includes a snapshot of FDA approvals from December, an exclusive roundup of critical NCCN guideline updates from 2024, and more.

BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy

January 4th 2025

BMS-986253 plus nivolumab/ipilimumab failed to improve responses or PFS in advanced melanoma after progression on or after a checkpoint inhibitor.

A 30-Year Commitment to Advancing Melanoma Care

January 1st 2025

Labeled as a strong and fair division chief, impactful mentor, and brilliant researcher, Lynn M. Schuchter, MD, continues to drive advances in melanoma with the aid of a collaborative and innovative atmosphere.

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies

December 31st 2024

Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a slideshow.

OncLive’s December Roundup of Key FDA Approvals in Oncology

December 30th 2024

Here is your snapshot of all therapeutic options greenlit by the FDA in December 2024 spanning tumor types.

Novel Therapies and Combinations Augment Melanoma Treatment Arsenal

December 25th 2024

Omid Hamid, MD, discusses recent advances in the melanoma treatment landscape and highlights the 21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®.

FDA Approves Cosibelimab for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

December 13th 2024

The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.

Dr Postow on the Potential Role for Triplet Regimens in Melanoma

December 5th 2024

Michael A. Postow, MD, discusses the potential role for triplet regimens in melanoma management.

NICE Recommends Tebentafusp Reimbursement for HLA-A*02:01+ Uveal Melanoma

December 4th 2024

NICE has recommended the reimbursement for tebentafusp in HLA-A*02:01–positive unresectable or metastatic uveal melanoma.

Dr Deek on Vismodegib Plus Radiation in Locally Advanced Unresectable Basal Cell Carcinoma

November 29th 2024

Matthew P. Deek, MD, discusses multidisciplinary approaches in treating locally advanced basal cell carcinoma.

Accelerated Approval Sought for RP1 Plus Nivolumab in Advanced Melanoma

November 22nd 2024

A biologics license application was submitted to the FDA seeking the approval of RP1 plus nivolumab for patients with PD-1 inhibitor–exposed melanoma.

Neoadjuvant Therapy NCCN Recommendations Take the Melanoma Field in a New Direction

November 22nd 2024

Douglas B. Johnson, MD, MSCI, unpacks NCCN guideline updates in melanoma, detailing how neoadjuvant and TIL therapies have been notable advancements.

The OncFive: Top Oncology Articles for the Week of 11/10

November 16th 2024

New datopotamab deruxtecan BLA in NSCLC filed to FDA, radiopharmaceutical meets rPFS end point in PSMA+ prostate cancer, and more.

RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy

November 11th 2024

RP1 plus nivolumab generated responses in advanced melanoma that progressed on or after prior anti–PD-1 therapy.